Published in Clin Infect Dis on June 05, 2001
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med (2014) 1.31
Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis (2004) 1.02
Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents. Antimicrob Agents Chemother (2010) 1.02
Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis (2010) 0.82
The role of the de novo pyrimidine biosynthetic pathway in Cryptococcus neoformans high temperature growth and virulence. Fungal Genet Biol (2014) 0.81
Utilization and comparative effectiveness of caspofungin and voriconazole early after market approval in the U.S. PLoS One (2014) 0.81
Counterpoint: alternative trial designs for antifungal drugs--time to talk. Clin Infect Dis (2001) 0.75
Combination Antifungal Therapy: A Review of Current Data. J Clin Med Res (2017) 0.75
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
Application of DNA typing methods to epidemiology and taxonomy of Candida species. J Clin Microbiol (1987) 13.21
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med (1994) 9.11
Map-based cloning of a protein kinase gene conferring disease resistance in tomato. Science (1993) 9.00
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother (1976) 8.54
A Candida albicans dispersed, repeated gene family and its epidemiologic applications. Proc Natl Acad Sci U S A (1988) 7.75
Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J (1991) 6.91
Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol (1982) 6.78
Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med (1974) 6.75
Apolipoproteins and ischaemic heart disease: implications for screening. Lancet (1994) 6.62
Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis (1991) 6.43
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet (2001) 6.24
Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) (1970) 5.98
Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods. Antimicrob Agents Chemother (1978) 5.94
Direct allelic variation scanning of the yeast genome. Science (1998) 5.90
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med (1979) 5.87
Variables influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine. Antimicrob Agents Chemother (1973) 5.84
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev (1999) 5.84
Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol (1984) 5.74
Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study. Ann Intern Med (1987) 5.74
Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.73
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis (1969) 5.58
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol (1986) 5.19
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
Serologic grouping of Cryptococcus neoformans. Proc Soc Exp Biol Med (1968) 4.97
Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother (1998) 4.95
Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother (1995) 4.92
Taxonomic studies on Filobasidiella species and their anamorphs. Antonie Van Leeuwenhoek (1982) 4.90
Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (1997) 4.75
Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med (1984) 4.73
Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med (1993) 4.72
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect (2012) 4.56
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis (1983) 4.42
Chronic mucocutaneous candidiasis: model-building in cellular immunity. Ann Intern Med (1971) 4.41
Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol (2000) 4.26
Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med (1991) 4.20
Chemotherapy of systemic mycoses (first of two parts). N Engl J Med (1974) 4.20
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet (2005) 4.17
Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis (2001) 4.01
Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis (1989) 4.01
Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol (1985) 3.97
Epidemiologic differences among serotypes of Cryptococcus neoformans. Am J Epidemiol (1977) 3.91
Miconazole in coccidiodomycosis. II. Therapeutic and pharmacologic studies in man. Am J Med (1976) 3.91
Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother (1982) 3.91
Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother (1982) 3.90
Group C streptococcal bacteremia: analysis of 88 cases. Rev Infect Dis (1991) 3.88
Treatment of invasive aspergillosis with itraconazole. Am J Med (1989) 3.87
Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis (1983) 3.86
Superconductivity at 43 K in SmFeAsO1-xFx. Nature (2008) 3.80
Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J Exp Med (1996) 3.76
Mouse model of pulmonary blastomycosis: utility, simplicity, and quantitative parameters. Am Rev Respir Dis (1978) 3.75
Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro. J Infect Dis (1972) 3.75
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis (2000) 3.70
Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med (1991) 3.69
A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med (1992) 3.65
Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev (1994) 3.58
Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs. Postgrad Med J (1979) 3.55
Distribution of alpha and alpha mating types of Cryptococcus neoformans among natural and clinical isolates. Am J Epidemiol (1978) 3.55
Control for rheumatoid factor in the latex test for cryptococcosis. Am J Clin Pathol (1971) 3.47
Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood (1997) 3.45
Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis (1999) 3.39
The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol (1974) 3.38
Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med (1994) 3.32
Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis (2005) 3.31
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis (1990) 3.19
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother (1997) 3.17
Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis (1992) 3.16
Capsular polysaccharides of Cryptococcus neoformans. Rev Infect Dis (1984) 3.10
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis (1998) 3.09
Critical role of germ tube formation in the pathogenesis of candidal vaginitis. Infect Immun (1984) 3.07
Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother (1996) 3.03
Methicillin-resistant Staphylococcus aureus: colonization and infection in a long-term care facility. Ann Intern Med (1991) 3.03
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother (1998) 3.00
In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother (1997) 2.99
Miconazole in coccidioidomycosis. I. Assays of activity in mice and in vitro. J Infect Dis (1975) 2.99